Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 37 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor TherapyCompletedNCT03132636Phase 2Results posted
• Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerCompletedNCT03132467Early Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesCompletedNCT03130959Phase 2Results posted
• A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03126591Phase 1Results posted
• Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic SarcomaCompletedNCT03123276Phase 1/2Results posted
• Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationTerminatedNCT03121534Phase 2Results posted
• Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerCompletedNCT03121352Phase 2Results posted
• Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaTerminatedNCT03120676Phase 2Results posted
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaCompletedNCT03117309Phase 2Results posted
• Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)CompletedNCT03117049Phase 3Results posted
• Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line TreatmentCompletedNCT03116152Phase 2Results posted
• A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersTerminatedNCT03115801Phase 2Results posted
• P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03113487Phase 2Results posted
• Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
• First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT03110107Phase 1/2Results posted
• Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedNCT03108495Phase 2Results posted
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 2Results posted
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT03106415Phase 1/2Results posted
• A Study of AGEN2034 in Advanced Tumors and Cervical CancerCompletedNCT03104699Phase 1/2Results posted
• Atezolizumab Immunotherapy in Patients With Advanced NSCLCCompletedNCT03102242Phase 2Results posted
• Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerCompletedNCT03101566Phase 2Results posted
• Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal CancerCompletedNCT03099382Phase 3Results posted
• A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadCompletedNCT03098550Phase 1/2Results posted
• Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginCompletedNCT03095274Phase 2Results posted
• Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT03094637Phase 2Results posted
• Durvalumab in HIV-1 Patients With Solid TumorsCompletedNCT03094286Phase 2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Dendritic Cell Vaccination in Patients With Advanced MelanomaCompletedNCT03092453Phase 1Results posted
• Pembrolizumab in Patients With Leptomeningeal DiseaseTerminatedNCT03091478Phase 2Results posted
• Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT03090737Phase 2Results posted
• Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging BiomarkerCompletedNCT03089606Phase 2Results posted
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03088540Phase 3Results posted
• Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerCompletedNCT03087760Phase 2Results posted
• Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03087019Phase 2Results posted
• Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNActive, not recruitingNCT03085719Phase 2Results posted
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.CompletedNCT03084471Phase 3Results posted
• Phase II Trial of Continuation Therapy in Advanced NSCLCCompletedNCT03083808Phase 2Results posted
• A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)CompletedNCT03083041Phase 2Results posted
• Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03082534Phase 2Results posted
• Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsCompletedNCT03081689Phase 2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT03077828Phase 2Results posted
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminatedNCT03075527Phase 2Results posted
• Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT03074318Phase 1/2Results posted
• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted
• A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT03071094Phase 1/2Results posted
• A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03069378Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results posted
• A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)CompletedNCT03066778Phase 3Results posted
• PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted
• Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)CompletedNCT03064490Phase 2Results posted
• Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial SarcomaCompletedNCT03063632Phase 2Results posted
• Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Phase 3Results posted
• Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results posted
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
• The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NeckCompletedNCT03057613Phase 2Results posted
• Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for SarcomaCompletedNCT03056001Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted
• Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTerminatedNCT03051672Phase 2Results posted
• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004TerminatedNCT03050814Phase 2Results posted
• SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03050554Phase 1/2Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475CompletedNCT03049618Phase 2Results posted
• Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03048500Phase 2Results posted
• Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaCompletedNCT03047928Phase 1/2Results posted
• Avelumab in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT03047473Phase 2Results posted
• Avelumab in Relapsed and Refractory Peripheral T-cell LymphomaCompletedNCT03046953Phase 2Results posted
• Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03044730Phase 2Results posted
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active, not recruitingNCT03043872Phase 3Results posted
• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted
• Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerCompletedNCT03043599Phase 1/2Results posted
• Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorTerminatedNCT03041181Phase 2Results posted
• Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)CompletedNCT03040999Phase 3Results posted
• A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03038100Phase 3Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)CompletedNCT03036488Phase 3Results posted
• Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerActive, not recruitingNCT03036098Phase 3Results posted
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCompletedNCT03029780Phase 2Results posted
• Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03029598Phase 1/2Results posted
• A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerTerminatedNCT03026166Phase 1/2Results posted
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results posted
• Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABCCompletedNCT03025880Phase 2Results posted
• Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast CancerCompletedNCT03025035Phase 2Results posted
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following NephrectomyTerminatedNCT03024996Phase 3Results posted
• Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaTerminatedNCT03024437Phase 1/2Results posted
• A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03023423Phase 1/2Results posted
• Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerCompletedNCT03021993Phase 2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Phase 3Results posted
• Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerCompletedNCT03018080Phase 2Results posted
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLActive, not recruitingNCT03016871Phase 2Results posted
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane RegimenCompletedNCT03016312Phase 3Results posted
• A Trial of Pembrolizumab for Refractory Atypical and Anaplastic MeningiomaTerminatedNCT03016091Phase 2Results posted
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results posted
• A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerCompletedNCT03015129Phase 2Results posted
• Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03014648Phase 2Results posted
• PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasTerminatedNCT03013491Phase 1/2Results posted
• Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedNCT03007732Phase 2Results posted
• Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyCompletedNCT03007407Phase 2Results posted

← Immune Checkpoint Inhibitors overview